Correlation of renal cortical blood perfusion and BP response after renal artery stenting

Siyu Wang1,2†, Sijie Zhang1,2,3†, Yan Li1,2, Na Ma1,2, Mengpu Li1,2, Hu Ai2,4, Hui Zhu2,5, Junhong Ren1,2✉, Yongjun Li2,6 and Peng Li7

1Department of Sonography, Beijing Hospital, National Center of Gerontology, Beijing, China, 1Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China, 1Graduate School of Peking Union Medical College, Beijing, China, 1Department of Cardiology, Beijing Hospital, National Center of Gerontology, Beijing, China, 1Department of Nuclear Medicine, Beijing Hospital, National Center of Gerontology, Beijing, China, 1Department of Vascular Surgery, Beijing Hospital, National Center of Gerontology, Beijing, China, 1The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Beijing, China

Background: This study aimed to observe the correlation between renal cortical blood perfusion (CBP) parameters and BP response in patients with severe renal artery stenosis (RAS) who underwent stenting.

Methods: This was a single-center retrospective cohort study. A total of 164 patients with unilateral severe RAS after successful percutaneous transluminal renal artery stenting in Beijing Hospital from October 2017 to December 2020 were included. According to the results of BP evaluated at 12 months, all patients were divided into the BP response group (n = 98) and BP nonresponse group (n = 66). The baseline clinical and imaging characteristics and follow-up data about 24 h ABPM and CBP were recorded and analyzed. Pearson correlation analysis was used to evaluate the relationship between CBP parameters and 24 h average SBP. Univariate and multivariate logistic regression analysis was used to evaluate the risk factors for BP response.

Results: Among 164 patients with severe RAS, there were 100 males (61.0%), aged 37–75 years, with an average of 56.8 ± 18.4 years, and average artery stenosis of 84.0 ± 12.5%. The BP nonresponse patients had a longer duration of hypertension, more current smoking subjects and diabetic patients, lower eGFR, increased number of hypertensive agents, and rate of insulin compared with the BP response group (P < 0.05). After PTRAS, patients in the BP response group were associated with significantly lower BP and improved CPB, characterized by increased levels of maximum intensity (iMAX), area under ascending curve (AUC1), area under the descending curve (AUC2), shortened rising time (RT), mean transit time (mTT), and prolonged time to peak intensity (TTP; P < 0.05). However, the BP nonresponse group was only associated with significantly reduced RT (P < 0.05) compared with baseline data. During an average follow-up of 11.5 ± 1.7 months, the BP response group was associated with significantly lower levels of SBP, DBP, 24 h average SBP, and 24 h average DBP compared with the nonresponse group (P < 0.05). Pearson correlation...
analysis showed that the the pre-operative CBP parameters, including IMAX ($r = 0.317$), RT ($r = 0.249$), AUC1 ($r = 0.614$), AUC2 ($r = 0.558$), and postoperative CBP parameters, including RT ($r = 0.283$), AUC1 ($r = 0.659$), and AUC2 ($r = 0.674$) were significantly positively correlated with the 24h average SBP, while the postoperative TTP ($r = -0.413$) and mTT ($r = -0.472$) were negatively correlated with 24h average SBP ($P < 0.05$). Multivariate Logistic regression analysis found that diabetes (OR = 1.294), NT-proBNP (OR = 1.395), number of antihypertensive agents (OR = 2.135), pre-operation IMAX (OR = 1.534), post-operation AUC2 (OR = 2.417), and baseline dDBP (OR = 2.038) were related factors for BP response (all $P < 0.05$).

**Conclusion:** Patients in the BP nonresponse group often have diabetes, a longer duration of hypertension, significantly reduced glomerular filtration rate, and heavier renal artery stenosis. CBP parameters are closely related to 24h average SBP, and pre-operation IMAX and post-operation AUC2 are markers for a positive BP response.

**KEYWORDS**
renal artery stenosis, 24h ambulatory blood pressure monitor, contrast-enhanced ultrasound, renal cortical blood perfusion, follow-up

---

### Introduction

Renal artery stenosis (RAS) is associated with increased levels of BP. RAS is a primary cause of secondary hypertension. It involves the large and medium renal arteries, and is a relatively common condition in aged patients with hypertension, especially those with refractory hypertension, with the prevalence may be as high as 10–40% (1). RAS is conditioned mainly by atherosclerotic renal artery stenosis (ARAS), which primarily affects patients ≥45 years and usually involves the aortic artery orifice or the proximal main renal artery (2). In most cases of ARAS, ranging from 53 to 80%, one kidney is affected, with the main artery to the second kidney being essentially normal, hence the “unilateral” RAS (3). Percutaneous transluminal renal artery stenting (PTRAS) has emerged as the primary revascularization strategy in most patients with hemodynamically significant ARAS. However, several clinical randomized controlled trials, such as Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) and Angioplasty and Stent for Renal Artery Lesions, demonstrated that subjects with ARAS had similar outcomes whether randomized to optimal medical therapy alone or optimal medical therapy plus renal artery stenting (4, 5). In the CORAL study, after a median follow-up of 3.8 years, renal function was not improved after stenting; However, patients in the stented cohort were associated with a significant decrease in SBP (−14 mmHg) and DBP (−7 mmHg). Furthermore, the SBP and DBP changes were achieved with fewer antihypertensive drugs (−1 drug) (5).

There are several proven clinical predictors of BP response after renal artery stenting. Multiple single-center observational studies demonstrated that the renal artery stenting had a beneficial effect on BP response in 20–58% of patients (6, 7), and indicated several clinical factors for BP response, such as the number of antihypertensive drugs (OR = 5.9), preoperative DBP (OR = 13.9), clonidine use (OR = 4.5) (8), and brain natriuretic peptide (BNP) (OR = 0.72) (9). In a retrospective study with 72 patients with resistant hypertension, Logistic regression analysis results showed that being younger (OR = 0.94), lower systolic daytime ambulatory BP (OR = 0.94), lower body mass index (OR = 0.82), and higher estimated glomerular filtration rate (eGFR) (OR = 2.73) were independent predictors for BP response after renal angioplasty (10). However, these markers had not been validated in prospective studies, and which patient obtains a positive BP response from renal artery stenting remains unclear.

Renal blood perfusion (CBP) may be associated with BP response after renal artery stent implantation. The kidney plays an important central role in the regulation of BP. Many experimental and physiological studies indicate that renal perfusion pressure is closely involved in maintaining BP. The kidney is a primary target organ for BP regulation (11). Renal artery perfusion pressure directly regulates sodium excretion and influences the activity of various vasoactive systems such as the renin-angiotensin-aldosterone (RAAS) system (12, 13). As a result, CBP assessed by contrast-enhanced ultrasound (CEUS) may be related to the BP response in renal artery stenting patients. Therefore, renal CBP parameters can be used as a marker of BP response. Our previous study showed that among patients with unilateral severe RAS who underwent stent implantation, those with improved CBP were associated with significantly improved BP control compared with patients.
with decreased CBP ($P < 0.001$) (14). However, there are few studies evaluating the relationship between renal CBP and BP response in RAS patients. Therefore, this study aimed to evaluate the relationship between CBP and BP response in RAS patients who underwent stent implantation.

**Methods**

**Patients**

This is a single-center retrospective cohort study. A total of 82 patients with unilateral severe ARAS after successful percutaneous transluminal renal artery stenting (PTRAS) in Beijing Hospital from October 2017 to December 2020 were included. There were 50 males (61.0%), aged 37–75 years, with an average artery stenosis of 84.0 ± 12.5%. This study has been registered in China Clinical Trial Registration Center (ChiCTR1800016252) and approved by the Institutional Review Board (IRB) of Beijing Hospital (No. 2018BJYYEC-043-02). Written consent was obtained for both the procedure and data collection in all cases.

**Inclusion and exclusion criteria**

Inclusion criteria: (1) aged 18–80 years; (2) RAS was diagnosed by digital subtraction angiography (DSA), with unilateral atherosclerotic RAS of 70–99% and contralateral RAS < 50% (13, 14); (3) long diameter of the affected kidney > 7 cm; (4) no residual stenosis or residual stenosis of < 30% assessed by immediate post-operative DSA examination; and (5) with complete 12 months’ follow-up data. Exclusion criteria: (1) unstable or severe cardiopulmonary dysfunction; (2) contrast agent allergy; (3) advanced tumors; and (4) poor CEUS images.

According to the results of APBM evaluated at 12 months, all patients were divided into the BP response group ($n = 98$) and BP nonresponse group ($n = 66$) (8). BP response was defined as a postoperative BP < 160/90 mmHg with a less number of antihypertensive drugs or post-operative DBP < 90 mmHg with the same drugs. BP nonresponse was defined as maintaining the same antihypertensive drugs, or postoperative BP drops > 10 mmHg, with a reduced number and/or dose of antihypertensive drugs (8). The types and measurements of common antihypertensive drugs refer to the "Guidelines for the Prevention and Treatment of Hypertension in China (2018 Revised Edition)" (15).

**Data collection**

The patient’s baseline characteristics, including age, gender, duration of hypertension and diabetes, and stenotic degree of renal artery were collected. In addition, routine kidney ultrasound examination parameters, such as kidney size, cortex thickness, and hemodynamic parameters, including the main renal artery peak systolic velocity (PSV), abdominal PSV, interlobar artery PSV, acceleration time, and resistance index, were recorded. Moreover, renal CBP’ features before and after PTRAS were also recorded. All data were kept in the RAS Clinical and Imaging Database designed by Medical Research Statistics Center, Fuwai Hospital.

**RAS diagnoses**

The current “gold standard” for RAS was digital subtraction angiography (DSA) and CEUS was used as a first-line screening method for evaluating RAS in our hospital (16). The Color Doppler ultrasound and CEUS examinations were performed with CA 1–7A (1–7 MHz) transducer on an R8S0 ultrasound instrument (SAMSUNG, Korea). After routine renal artery ultrasonography, patients were injected with SonoVue (Sulfur Hexafluoride Microbubbles, Bracco, Milan, Italy) bolus two times into the upper limb vein for each kidney, including the main renal artery (dose, 1.0 ml/kidney) and renal CBP (dose, 1.2 ml/kidney) examination, followed by 5.0 ml saline for each bolus. First, patients were examined with normal breathing in the lateral position, and the dynamic contrast-enhanced renal artery imaging was stored for 1.0 min from the original site to the kidney hilum. The main renal artery lesion included the position, length, and diameter stenosis ratio. The degree of RAS was calculated as $1–($diameter of the stenosis/diameter of the normal portion distal to the stenosis$) \times 100\%$ in the artery phase of the enhanced image. And then the maximum long-axis section of the kidney was fixed to be perpendicular to the acoustic beam direction, SonoVue was injected again to continuously observe and store the real-time contrast agent perfusion of the renal cortical for 3 min (17, 18). Ultrasound instrument settings were kept constant during the entire procedure, including the contrast mechanical index MI of 0.08, the image depth of 14 cm, and the gain of 60 dB. The interval between each contrast agent injection was 15 min.

**CBP Assessment**

After all the examination procedures, the time-intensity curve (TIC) of renal cortical regions of interest (ROI) was analyzed using TomTec Imaging Systems (Germany) to determine the parameters of renal cortical microvascular perfusion, including the area under ascending curve (AUC1), area under the descending curve (AUC2), rising time (RT), time to peak intensity (TTP), maximum intensity (IMAX, with respect to the IMAX of the reference ROI), and mean transit time (MTT; Figure 1). Experts from the Departments of
Sonography (Na Ma, Jun-Hong Ren), Vascular Surgery (Yong-Jun Li), and Cardiology (Hu Ai) independently determined the RAS diagnoses, and two experienced sonographers (Na Ma and Jun-Hong Ren) reviewed the CBP.

24 h ambulatory BP monitoring

All patients wore an ABPM-05 ambulatory BP monitor (ABPM; Merrill Lynch, USA) on their left upper arm for 24 h, and kept the sea level at rest during each measurement. From 6:00 to 22:00, the day-time BP will be measured every 20 min, and between 22:00 and 6:00 the next day, the night-time BP will be measured every 1 h. And the following are recorded: 24 h average SBP, 24 h average DBP, daytime systolic BP (dSBP), dDBP, nighttime systolic BP (nSBP), and nDBP.

Statistical analyses

Data analysis was performed through STATA 13.0 statistical software (version 14.0; StataCorp, College Station, TX, USA). Normal distribution of measurement data was expressed as mean and SD, comparison between groups was analyzed by t-test or one-way ANOVA; non-normally distributed measurement data were represented by median (interquartile range) and non-parametric tests were used for comparison between groups; countable data were expressed as percentages and comparisons between groups were detected by the χ² test. The Pearson correlation analysis was used to evaluate the relationship between pre-or post-operative CBP parameters and 24 h average SBP measured at 12 months of follow-up, P < 0.05 was considered statistically significant.

Results

Baseline data comparison between the two groups

The BP nonresponse group had a longer duration of hypertension, more current smoking subjects and diabetic patients, lower eGFR, higher NT-proBNP, increased number of hypertensive agents, and rate of insulin compared with the BP response group (all P < 0.05) (Table 1).

Pre- and post-operative renal CBP data

Before stent implantation, the CBP of the two groups was significantly different (P < 0.05). Compared with the BP nonresponse group, the response group had better cortical perfusion, which was manifested as a significant decrease in IMAX, a shortened RT and TTP time, a prolonged mTT time, and a significant increase in AUC1 and AUC2 (P < 0.05).

After stent implantation, the BP nonresponse group was associated with significantly reduced RT (P < 0.05), but other CBP parameters (IMAX, TTP, mTT, AUC1, and AUC2) did not change significantly (P > 0.05) (Figure 2). In the BP response
TABLE 1  Comparison of the baseline data of the study groups.

| Characteristics | Nonresponse group (n = 66) | Response group (n = 98) | t/Z/χ² value | P-value |
|-----------------|---------------------------|------------------------|---------------|---------|
| Baseline data   |                           |                        |               |         |
| Age, yr         | 55.6 ± 14.7               | 54.3 ± 12.8            | 0.291         | 0.771   |
| Male, n (%)     | 38 (57.6)                 | 62 (63.3)              | 0.5337        | 0.464   |
| Current smoking, n (%) | 42 (63.6)    | 42 (42.9)              | 6.816         | 0.009   |
| BMI, kg/m²      | 26.1 ± 3.4                | 26.4 ± 3.1             | 0.584         | 0.560   |
| Duration of HP, yr | 10.9 ± 4.2              | 7.3 ± 2.2              | 7.158         | 0.001   |
| Previous history|                           |                        |               |         |
| Diabetes, n (%) | 40 (60.6)                 | 46 (64.9)              | 0.954         | 0.364   |
| Hyperlipidemia, n (%) | 44 (66.7)    | 64 (65.3)              | 0.033         | 0.857   |
| OMI, n (%)      | 32 (48.5)                 | 40 (40.8)              | 0.942         | 0.334   |
| Atrial fibrillation, n (%) | 28 (42.4)     | 36 (46.7)              | 0.537         | 0.464   |
| Lab. test       |                           |                        |               |         |
| eGFR(ml/min/1.73m²²) | 50.7 ± 15.7            | 56.7 ± 13.9            | 2.572         | 0.011   |
| NT-proBNP       | 379.2 ± 203.1             | 327.4 ± 154.9          | 1.951         | 0.033   |
| LVEF, %         | 47.3 (38.4,58.6)          | 49.7 (43.7,55.2)       | 0.625         | 0.533   |
| Degree of RAS, % | 81.4 ± 11.9              | 80.8 ± 10.2            | 0.345         | 0.731   |
| Drug treatment  |                           |                        |               |         |
| Antihypertensive agents, n | 43 ± 1.7                | 38 ± 1.8               | 0.834         | 0.038   |
| CCB³             | 65 (98.5)                 | 98 (100)               | 1.494         | 0.222   |
| β-blocker        | 26 (39.4)                 | 32 (32.7)              | 0.874         | 0.376   |
| ACEI/ARB        | 13 (19.7)                 | 20 (20.4)              | 0.012         | 0.911   |
| Diuretic        | 22 (33.3)                 | 21 (21.4)              | 2.889         | 0.089   |
| Statins, n (%)  | 36 (54.3)                 | 50 (51.0)              | 0.197         | 0.658   |
| Insulin, n (%)  | 28 (42.4)                 | 28 (28.6)              | 3.367         | 0.047   |
| Antiplatlet therapy, n (%) | 44 (66.7)    | 64 (65.3)              | 0.033         | 0.857   |
| Anticoagulant, n (%) | 26 (39.4)               | 34 (34.7)              | 0.376         | 0.540   |

³CCB included amlodipine, L-amlodipine, nifedipine, felodipine, lercanidipine; BMI, body mass index; HP, hypertension; OMI, old myocardial infarction; Scr, serum creatinine; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; RAS, renal artery stenosis; CCB, calcium channel blocker; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

Results of ABPM at 12-month follow-up

The baseline BP levels of the two groups were similar, and there were no significant differences in dSBP, nSBP, and 24 h average SBP (P > 0.05). However, levels of dDBP, nDBP, and 24 h average DBP were significantly higher in the response group (P < 0.05).

At the 12-month follow-up, compared with baseline level, the BP nonresponse group was associated with significantly reduced dSBP, nSBP, and 24 h average SBP (P < 0.05), but dDBP, nDBP, and 24 h average DBP did not change significantly (P > 0.05).

The BP response group was associated with significantly reduced SBP, nSBP, nDBP, 24 h average SBP, and 24 h average DBP (P < 0.05), but the levels of dDBP did not change significantly (P > 0.05). Additionally, at 12 months of follow-up, compared with the nonresponse group, the response group was associated with significantly lower levels of dSBP, dDBP, nSBP, nDBP, 24 h average SBP, and 24 h average DBP (P < 0.05) (Table 3).

Correlation of CBP and 24 h average SBP

As shown in Figure 3, the pre-operative CBP parameters, IMAX (r = 0.317), RT (r = 0.249), AUC1 (r = 0.614), and AUC2 (r = 0.558) were all significantly positively correlated with the 24 h average SBP at follow-up; Postoperative CBP parameters, RT (r = 0.283), AUC1 (r = 0.659), and AUC2 (r = 0.674)
Routine ultrasound and CEUS images of a 65-year-old man with 70% right renal ostial stenosis. (A) Color Doppler flow (left), Doppler frequency spectrum (middle), and CEUS (right) images of the long axis section of right renal artery before PTRAS. (B) After stent implantation, renal artery blood flow images (left) and the peak systolic velocity (middle) of stenosis were corrected, and contrast beam filling (right) displayed normal. RA, renal artery; AO, abdominal aorta. (A) Pre-operative cortical blood perfusion, IMAX (%): 85.5, RT (s): 7.7, TTP (s): 8.3, mTT (s): 42.5, AUC1: 47.5, AUC2: 308.4. (B) Post-operative cortical blood perfusion, IMAX (%): 72.5, RT (s): 6.7, TTP (s): 7.3, mTT (s): 27.9, AUC1: 34.6, AUC2: 194.4. Changes in cortical blood perfusion before (A) and after (B) stent implantation of a 57-year-old woman with severe stenosis of the right renal artery in the BP nonresponse group.
TABLE 2 Cortical blood perfusion parameters before and after stent implantation.

| Parameters | Pre/post-operation | Nonresponse group (n = 66) | Response group (n = 98) | t-value | P-value |
|------------|--------------------|---------------------------|------------------------|---------|---------|
| Imax (%)   | Pre-               | 765.4 ± 224.7             | 717.2 ± 222.6          | 1.355   | 0.177   |
|            | Post-              | 875.3 ± 231.2             | 1242.7 ± 154.6         | 12.202  | 0.001   |
|            | t-value            | 2.769                     | 19.195                 | 0.006   | 0.001   |
| RT(s)      | Pre-               | 6.6 ± 2.2                 | 5.8 ± 1.7              | 2.622   | 0.011   |
|            | Post-              | 6.0 ± 1.5                 | 11.9 ± 2.2             | 19.005  | 0.0001  |
|            | t-value            | 1.831                     | 21.719                 | 0.035   | 0.0001  |
| TTP(s)     | Pre-               | 6.4 ± 3.4                 | 5.8 ± 1.7              | 1.493   | 0.137   |
|            | Post-              | 7.2 ± 2.7                 | 12.9 ± 3.2             | 11.895  | 0.0001  |
|            | t-value            | 1.497                     | 19.397                 | 0.137   | 0.0001  |
| mTT(s)     | Pre-               | 46.3 ± 27.4               | 59.6 ± 21.2            | 3.497   | 0.001   |
|            | Post-              | 39.8 ± 23.5               | 48.4 ± 17.6            | 2.767   | 0.008   |
|            | t-value            | 1.463                     | 4.024                  | 0.146   | 0.001   |
| AUC1(dB × s)| Pre-               | 50.2 ± 27.4               | 61.3 ± 26.4            | 2.601   | 0.010   |
|            | Post-              | 64.3 ± 25.6               | 103.4 ± 33.7           | 7.996   | 0.001   |
|            | t-value            | 3.055                     | 9.735                  | 0.005   | 0.0001  |
| AUC2(dB × s)| Pre-               | 247.3 ± 179.4             | 275.5 ± 150.3          | 1.089   | 0.278   |
|            | Post-              | 337.4 ± 153.1             | 563.2 ± 202.5          | 7.695   | 0.001   |
|            | t-value            | 3.104                     | 11.294                 | 0.002   | 0.0001  |

were significantly positively correlated with the 24 h average SBP, and TTP ($r = -0.413$) and mTT ($r = -0.472$) were negatively correlated with 24 h average SBP ($P < 0.05$) (Figure 4).

**Discussion**

In our study, patients in the BP nonresponse group often have diabetes, a longer duration of hypertension, significantly reduced glomerular filtration rate, and heavier renal artery stenosis. CBP parameters, especially postoperative AUC1 and AUC2, are positively related to 24 h average SBP, and IMAX and AUC2 are positively related to BP response.

Previous studies indicated several clinical and laboratory markers for BP response in RAS patients. Modrall and its colleagues enrolled 149 patients who underwent primary renal artery stenting. Patients were divided into the "responders group" and nonresponder group. BP responders were defined based on modified AHA guidelines: BP $< 160/90$ mmHg with fewer antihypertensive drugs or DBP $< 90$ mmHg with the same drugs. All others were regarded as "nonresponders." After a median follow-up of 19 months, the study indicated that a favorable BP response rate was 34%. Furthermore, three independent predictors of a positive BP response were identified: (1) with four or more antihypertensive drugs (OR = 29.9, $P = 0.0001$), (2) preoperative DBP $> 90$ mmHg (OR = 31.4, $P = 0.0011$), and (3) with preoperative clonidine use (OR = 7.3, $P = 0.029$) (8). In addition, among subjects with three
antihypertensive drugs, those with ipsilateral kidney volume $\geq$ 150 cm$^3$ had a 3-fold increased BP response rate compared with patients with smaller kidneys ($P = 0.018$) (8). However, that study’s sample size was small. Moreover, those markers for BP response have not been independently validated in other studies (19). Subsequently, they conducted another study to validate these markers using the CORAL trial data. There were 436 subjects who underwent stent implantation in the CORAL
TABLE 3 The 24 h ABP at baseline and 12 months of follow-up between groups.

| BP      | Time    | Nonresponse group (n = 66) | Response group (n = 98) | t-value | P-value |
|---------|---------|---------------------------|-------------------------|---------|---------|
| dSBP    | Baseline| 154.2 ± 11.4              | 153.9 ± 11.6            | 0.164   | 0.870   |
|         | Follow up| 139.1 ± 9.7               | 135.1 ± 8.4             | 2.809   | 0.006   |
|         | t-value | 8.196                     | 12.995                  |         |         |
|         | P-value | 0.0001                    | 0.0001                  |         |         |
| dDBP    | Baseline| 89.2 ± 10.2               | 91.2 ± 11.1             | 1.169   | 0.244   |
|         | Follow up| 86.4 ± 6.3                | 84.7 ± 8.6              | 1.376   | 0.171   |
|         | t-value | 1.897                     | 4.583                   |         |         |
|         | P-value | 0.061                     | 0.001                   |         |         |
| nSBP    | Baseline| 149.4 ± 9.7               | 150.3 ± 12.3            | 0.499   | 0.619   |
|         | Follow up| 137.5 ± 8.1               | 131.4 ± 5.8             | 5.620   | 0.001   |
|         | t-value | 7.651                     | 13.759                  |         |         |
|         | P-value | 0.0001                    | 0.0001                  |         |         |
| nDBP    | Baseline| 88.4 ± 11.3               | 89.5 ± 13.9             | 0.545   | 0.594   |
|         | Follow up| 85.2 ± 5.9                | 82.6 ± 6.2              | 2.685   | 0.008   |
|         | t-value | 2.039                     | 4.488                   |         |         |
|         | P-value | 0.043                     | 0.001                   |         |         |
| 24 h SBP| Baseline| 151.3 ± 9.2               | 151.6 ± 12.7            | 0.165   | 0.869   |
|         | Follow up| 140.3 ± 6.7               | 135.3 ± 5.1             | 5.418   | 0.001   |
|         | t-value | 7.852                     | 11.791                  |         |         |
|         | P-value | 0.0001                    | 0.0001                  |         |         |
| 24 h DBP| Baseline| 88.7 ± 11.8               | 90.1 ± 12.4             | 0.723   | 0.471   |
|         | Follow up| 85.3 ± 7.4                | 83.2 ± 7.3              | 1.701   | 0.046   |
|         | t-value | 1.907                     | 4.747                   |         |         |
|         | P-value | 0.058                     | 0.001                   |         |         |

Baseline SBP and DBP were 149 mmHg and 78 mmHg in the stented cohort, respectively (19). Multilogistic regression analysis results confirmed the three independent markers for BP response, including ≥4 antihypertensive drugs (OR = 5.9, P < 0.001), preoperative DBP >90 mmHg (OR = 13.9, P < 0.001), and preoperative clonidine use (OR = 4.52, P = 0.008) (19). Meanwhile, the BP response rate increased incrementally with the increase in the number of markers (P < 0.0001) (19). In another study conducted by Silva et al. 27 RAS patients who underwent stent placement were enrolled. The authors found that BNP was elevated before stenting (187 pg/ml) and fell within 24 h after stenting (median, 96 pg/ml), and remained low (85 pg/ml) at follow-up (20). Furthermore, they showed that patients with a higher baseline BNP (>80 pg/ml) had a higher rate of BP improvement than those with lower BNP (<80 pg/ml) (20). In contrast with this study, Jaff et al. indicated no correlation between BP response and baseline BNP (21). Meanwhile, in a patient-level meta-analysis of 901 subjects from five prospective studies, Weinberg et al. found that elevated baseline SBP of more than 150 mmHg was also significantly associated with BP response (OR = 1.76) (22). Prajapati et al. also showed that male gender (P = 0.016), higher baseline SBP (P < 0.01), DBP (P < 0.04), no. of antihypertensive drugs (P < 0.01), and low GFR <60 ml/min (P < 0.01) were correlated with poor BP response (23). Rocha-Singh et al. identified the preoperative MAP of >110 mmHg (OR = 2.90) and bilateral renal stenoses (OR = 4.60) as markers of BP response (24). In line with previous studies (25), we confirmed that diabetes (OR = 3.294), number of antihypertensive agents (OR = 7.485), NT-proBNP (OR = 2.395), and dDBP (OR = 9.238) were markers of BP response.

Recently, several studies proved that CBP was considered to be a sensitive indicator for BP response after stent implantation. In a small-sample observational study involving 68 significant RAS (≥70% stenosis) patients, who underwent stenting and with refractory hypertension (BP ≥140/90 mmHg despite therapy with two or more antihypertensive drugs), the authors evaluated the renal perfusion with renal frame count (RFC; angiographic frame number for contrast to reach distal renal parenchyma after initial renal artery opacification) and changes of BP (baseline and at 6-month follow-up) were recorded (26). The primary outcome was the clinical response, which was defined as a reduction in SBP >10 mmHg with the same or fewer antihypertensive drugs. The study indicated that subjects...
FIGURE 4
Correlation between pre- and post-operative CBP and 24 h average SBP assessed at 12-month follow-up.
with RFC > 30 had significant reductions in SBP, DBP, and MAP (P < 0.05). Moreover, those with baseline RFC > 30 was associated with a significantly increased rate of clinical response to stenting (93.5% vs. 73.0%, P = 0.027) (26). Another subsequent trial confirmed these findings and showed that BP responders had a greater decrease in RFC and 78.6% of subjects with >4 RFC decrease were BP responders (P = 0.024) (27). Therefore, renal perfusion was a marker for BP response. Besides, renal artery pressure-related index was also associated with BP response. Mangiacapra and its colleagues enrolled 53 consecutive hypertensive subjects with unilateral RAS and evaluated the translesional pressure gradient (TPG).

After a mean follow-up of 3 months, they found that dopamine-induced TPG (>20 mmHg) was the only maker of BP response (AUC, 0.77; 95% CI 0.64–0.90) (28). In another study, Leesar et al. compared the predictive values of TPG [resting systolic gradient, hyperemic systolic gradient (HSG), fractional flow reserve (FFR), mean gradient], intravascular ultrasound (IVUS), and angiographic index for hypertension improvement. They found that compared with FFR (AUC = 0.85), IVUS area stenosis (AUC = 0.82) and diameter stenosis by angiography (AUC = 0.74), HSG (AUC = 0.74) was the best marker for hypertension improvement. Furthermore, multivariate logistic regression analysis indicated that HSG was the only independent parameter for predicting BP response (OR = 1.39, 95% CI 1.05–1.65) (29). However, Mitchell et al. found the opposite results. In a prospective study that only enrolled 17 unilateral RAS patients, they showed that TPG parameters (resting, peak, or hyperemic) alone could not differentiate BP responders, and renal FFR was a marker for BP response (30). However, this study's sample size is small and patients were only followed for 90 d. Therefore, it could not completely exclude the results of other studies. The AHA panel recommends that a peak systolic TPG ≥ 20 mmHg, or mean gradient ≥10 mmHg, is the indicator for revascularization in patients with symptomatic RAS. In our study, after an average follow-up of 11.5 months, the BP response group was associated with significantly lower levels of SBP, DBP, 24 h average SBP, and 24 h average DBP compared with the nonresponse group (P < 0.05). Pearson correlation analysis showed that the pre-operative CBP parameters, including IMAX (r = 0.317), RT (r = 0.249), AUC1 (r = 0.614), and AUC2 (r = 0.558), and postoperative CBP parameters, including RT (r = 0.283), AUC1 (r = 0.659), and AUC2 (r = 0.674), were significantly positively correlated with the 24 h average SBP, while the postoperative TTP (r = −0.413) and mTT (r = −0.472) were negatively correlated with 24 h average SBP (P < 0.05). Furthermore, multivariate Logistic regression analysis demonstrated that diabetes (OR = 1.294), NT-proBNP (OR = 1.395), number of antihypertensive agents (OR = 2.135), pre-operation IMAX (OR = 1.534), post-operation AUC2 (OR = 2.417), and baseline dDBP (OR = 2.038) were related factors for BP response (all P < 0.05). AUC2 is the index for renal perfusion and IMAX is closely related to renal artery pressure. Therefore, RBP parameters, preoperative IMAX, and postoperation AUC2 are makers of a positive BP response. However, we did not assess the TPG, FFR, and IVUS area stenosis and could evaluate the predictive value for BP response among these parameters.

### Limitations

This study had some limitations. (1) This study was a single-center cohort with a small sample. (2) All patients included in our study had atherosclerotic RAS, and those with a non-atherosclerotic reason of RAS, such as Takayasu’s arteritis and fibromuscular dysplasia, may have different characteristics, rate of BP response, and its related factors (31). (3) Patients enrolled were often middle-aged and elderly.

| Risk factor | Univariate | Multivariate |
|-------------|------------|--------------|
| OR | 95% CI | P-value | OR | 95% CI | P-value |
| Duration of HP | 2.091 | 1.287–3.397 | 0.003 | — | — | — |
| Smoking | 1.628 | 1.153–2.299 | 0.06 | — | — | — |
| Diabetes | 2.736 | 1.554–4.817 | 0.005 | 1.294 | 1.013–1.628 | 0.039 |
| eGFR | 1.954 | 1.176–3.247 | 0.01 | — | — | — |
| NT-proBNP | 3.703 | 1.584–8.657 | 0.03 | 1.395 | 1.115–1.745 | 0.004 |
| Number of antihypertensive agents | 4.189 | 2.072–8.469 | 0.001 | 2.135 | 1.236–3.688 | 0.007 |
| Pre-operation IMAX | 2.872 | 1.381–5.973 | 0.05 | 1.534 | 1.112–2.116 | 0.009 |
| Post-operation RT | 1.827 | 1.229–2.716 | 0.003 | — | — | — |
| Post-operation AUC1 | 3.554 | 1.503–8.404 | 0.04 | 1.627 | 1.143–2.316 | 0.007 |
| Post-operation AUC2 | 4.872 | 2.779–13.343 | 0.02 | 2.417 | 1.295–4.188 | 0.002 |
| Baseline dDBP | 3.703 | 1.282–10.696 | 0.016 | 2.038 | 1.296–3.305 | 0.002 |
| Baseline nDBP | 2.412 | 1.271–4.577 | 0.007 | — | — | — |

### TABLE 4 Univariate and multivariate Logistic regression analysis.
and had several atherosclerotic-related factors. Therefore, those younger patients with few atherosclerotic-related factors may have different related factors for renal function deterioration (31). (4) In the clinic, more than 1/2 of moderate-to-severe RAS patients had bilateral lesions and both kidneys were related to BP response. However, patients included in our study had unilateral RAS (31). (5) In addition, longer follow-up data are needed to evaluate the prognosis (32). More high-quality studies with large sample size and long follow-ups are warranted to validate these findings (33).

Conclusion

In conclusion, patients in the BP nonresponse group often have diabetes, a longer duration of hypertension, significantly reduced glomerular filtration rate, and heavier renal artery stenosis. CBP parameters are closely related to 24 h average SBP, and pre-operation IMAX and post-operation AUC2 are markers for a positive BP response. However, more studies are warranted to validate these findings.

Data availability statement

The raw data supporting the conclusions of this article will be made available from the corresponding author by request.

Ethics statement

The studies involving human participants were reviewed and approved by the Beijing Hospital. The patients/participants provided their written informed consent to participate in this study.

References

1. Safian RD. Renal artery stenosis. Prog Cardiovasc Dis. (2021) 65:60–70. doi: 10.1016/j.pcad.2021.03.003
2. Tafur JD, White CJ. Renal artery stenosis: when to revascularize in 2017. Curr Probl Cardiol. (2017) 42:110–35. doi: 10.1016/j.cpcardiol.2017.01.004
3. Prince M, Tafur JD, White CJ. When and how should we revascularize patients with atherosclerotic renal artery stenosis? JACC Cardiovasc Interv. (2019) 12:505–17. doi: 10.1016/j.jcin.2018.10.023
4. Investigator ASTRAL, Wheatley K, Ives N, Gray R, Kalra PA, Moss JG, et al. Revascularization versus medical therapy for renal-artery stenosis. N Engl J Med. (2009) 361:1953–62. doi: 10.1056/NEJMoa0905368
5. Cooper CJ, Murphy TP, Cutlip DEK, Henrich W, Reid DM, et al. Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med. (2014) 370:13–22. doi: 10.1056/NEJMoa1310753
6. Nolan BW, Schmermerhorn ML, Rowell E, Powell RJ, Fillinger ME, Bracclio EM, et al. Outcomes of renal artery angioplasty and stenting using low-profile systems. J Vasc Surg. (2005) 41:46–52. doi: 10.1016/j.jvs.2004.10.027
7. Beck AW, Nolan BW, De Martino R, Yuo TH, Tanaki WJ, Walsh DB, et al. Predicting blood pressure response after renal artery stenting. J Vasc Surg. (2010) 51:380–5. doi: 10.1016/j.jvs.2009.08.088
8. Modrall JG, Rosero EB, Leonard D, Timaran CH, Anthony T, Arko FA, et al. Clinical and kidney morphologic predictors of outcome for renal artery stenting: data to inform patient selection. J Vasc Surg. (2011) 53:1282–9. doi: 10.1016/j.jvs.2010.11.103
9. Murphy TP, Cooper CJ, Matsumoto AH, Cutlip DE, Pencina KM, Jamerson K, et al. Renal artery stent outcomes: effect of baseline blood pressure, stenosis severity, and translesion pressure gradient. J Am Coll Cardiol. (2015) 66:2487–94. doi: 10.1016/j.jacc.2015.09.073
10. Courand PY, Dinic M, Lorthioir A, Bobrie G, Grataloup C, Denarit N, et al. Resistant hypertension and atherosclerotic renal artery stenosis: effects of angioplasty on ambulatory blood pressure. a retrospective uncontrolled single-center study. Hypertension. (2019) 74:1516–23. doi: 10.1161/HYPERTENSIONAHA.119.13393
11. Hall JE, Brands MW, Shek EW. Central role of the kidney and abnormal fluid volume control in hypertension. J Hum Hypertens. (1996) 10:633–9.

Author contributions

SW and SZ wrote the main manuscript text. YanL, NM, ML, HA, HZ, and PL analyzed the data. JR designed this work. All authors contributed to the article and approved the submitted version.

Funding

This study was funded by the National High Level Hospital Clinical Research Funding (No. BJ-2018-198), Basic Research Project of the Central Academy of Medical Sciences of China (No. 2019PT320012), Beijing Science and Technology Project (No. Z211100002921011), and National Key R&D Program of China (No. 2020YFC2008100).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
12. Ivy JR, Bailey MA. Pressure natriuresis and the renal control of arterial blood pressure. J Physiol. (2014) 592:3955–67. doi: 10.1113/jphysiol.2014.271676

13. Cowley AW, Romain RJ, Fenoy PJ, Mattison DL. Effect of renal medullary circulation on arterial pressure. J Hypertens Suppl. (1992) 10:S187–93. doi: 10.1097/00004872-199212000-00021

14. Sun YJ, Wang SY, Ma N, Guo FJ, Li MP, Ai H, et al. An observational study of the effect of baseline renal CCB with contrast-enhanced ultrasound on short-term outcomes of stent implantation for severe renal artery stenosis. Chin J Ultrasoundogr. (2021) 30:944–9. doi: 10.3760/cma.j.cn131148-20210330-00301

15. Jiang XL, Zou YB. Chinese expert consensus for the diagnosis and management of renal artery stenosis. Chin Circul J. (2017) 32:835–44. doi: 10.3969/j.issn.1000-3614.2017.09.027

16. Ultrasound Branch of Chinese Medical Doctor and Association National Center of Gerontology. Chinese expert consensus on methods and procedures of renal artery contrast-enhanced ultrasound (2021 Edition). Chin J Ultrasoundogr. 30:921–6 (2021). doi: 10.3760/cma.j.cn131148-20210827-00685

17. Ren JH. Standardized thought of examination and operation with contrast-enhanced ultrasound for diagnosis of renal artery stenosis. Nutr Med J. China. (2020) 100:1281–3. doi: 10.3760/cma.j.cn12137-202002-00561

18. Ren JH, Wang SY, Ma N, Sun YJ, Zhang YW, Guo FJ, et al. Rationale and study design for one-stop assessment of renal artery stenosis and renal microvascular perfusion with contrast-enhanced ultrasound for patients with suspected renovascular hypertension. Chin Med J (2019) 132:63–8. doi: 10.3760/CMA.J.0000000000000002

19. Modrall JG, Zhu H, Weaver FA. Clinical predictors of blood pressure response after renal artery stenting. J Vasc Surg. (2020) 72:1269–75. doi: 10.1016/j.jvs.2019.12.041

20. Silva JA, Chan AW, White CJ, Collins TJ, Jenkins JS, Reilly JP, et al. Elevated brain natriuretic peptide predicts blood pressure response after stent revascularization in patients with renal artery stenosis. Circulation. (2005) 111:328–33. doi: 10.1161/01.CIR.0000153271.77341.9F

21. Jaff MR, Rates M, Sullivan T, Popma J, Guo X, Zuzghi M, et al. Significant reduction in systolic blood pressure following renal artery stenting in patients with uncontrolled hypertension: results from the HERCULES trial. Catheter Cardiovasc Interv. (2012) 80:234–50. doi: 10.1002/ccd.24449

22. Weinberg I, Keyes MJ, Giri J, Rogers KR, Olin JW, White CJ, et al. Blood pressure response to renal artery stenting in 901 patients from five prospective multicenter FDA-approved trials. Catheter Cardiovasc Interv. (2014) 83:603–9. doi: 10.1002/ccd.25263

23. Praipapati JS, Jain SR, Joshi H, Shah S, Sharma K, Sahoo S, et al. Response of blood pressure after percutaneous transluminal renal artery angioplasty and stenting. World J Cardio. (2013) 5:247–53. doi: 10.4330/wjc.v5.i7.247

24. Rocha-Singh KJ, Mishkel GJ, Katholi RE, Ligon RA, Armbruster JA, McShane KJ, et al. Clinical predictors of improved long-term blood pressure control after successful stenting of hypertensive patients with obstructive renal artery atherosclerosis. Catheter Cardiovasc Interv. (1999) 47:167–72.

25. Mishima E, Suzuki T, Ito S. Selection of Patients for Angioplasty for Treatment of Atherosclerotic Renovascular Disease: Predicting Responsive Patients. Am J Hypertens. (2020) 33:391–401. doi: 10.1093/ajh/hpaa016

26. Khan Z, Tolia S, Sanam K, Gholkar G, Zughab M, Naik S, et al. Is there still a role for renal artery stenting in the management of renovascular hypertension - A single-center experience and where do we stand? Cardivasc Revusc Med. (2019) 20:202–6. doi: 10.1016/j.carev.2018.06.008

27. Naghi J, Palakodeti S, Ang L, Reeves R, Patel M, Mahmud E, et al. Renal frame count: a measure of renal flow that predicts success of renal artery stenting in hypertensive patients. Catheter Cardiovasc Interv. (2015) 86:304–9. doi: 10.1002/ccd.23946

28. Mahmud E, Smith TW, Palakodeti V, Zaidi O, Ang L, Mitchell CR, et al. Renal frame count and renal blush grade: quantitative measures that predict the success of renal stenting in hypertensive patients with renal artery stenosis. JACC Cardiovasc Interv. (2008) 1:286–92. doi: 10.1016/j.jcin.2008.03.012

29. Mangiapacca E, Trana C, Sarno G, Davidicavicu G, Prettasieiwicz M, Muller O, et al. Translesional pressure gradients to predict blood pressure response after renal artery stenting in patients with renovascular hypertension. JACC Cardiovasc Interv. (2010) 3:537–42. doi: 10.1016/j.jcin.2010.11.002

30. Leesar MA, Varma J, Shapura A, Fabsah J, Raza ST, Elghoul Z, et al. Prediction of hypertension improvement after stenting of renal artery stenosis: comparative accuracy of translesional pressure gradients, intravascular ultrasound, and angiography. J Am Coll Cardiol. (2009) 53:2363–71. doi: 10.1016/j.jacc.2009.03.031

31. Mitchell JA, Subramanian R, White CJ, Soukas PA, Almagor Y, Stewart RE, et al. Predicting blood pressure improvement in hypertensive patients after renal artery stent placement: renal fractional flow reserve. Catheter Cardiovasc Interv. (2007) 69:685–9. doi: 10.1002/ccd.21095

32. Giroux MF, Soulier G, Thérasse E, Nicolet V, Froment D, Courtois M, et al. Percutaneous revascularization of the renal arteries: predictors of outcome. J Vasc Interv Radiol. (2000) 11:713–20. doi: 10.1016/S1051-0443(07)61629-7

33. Modrall JG, Timaran CH, Rosero EB, Chung J, Plummer M, Valentine RJ, et al. Longitudinal changes in kidney parenchymal volume associated with renal artery stenting. J Vasc Surg. (2012) 55:774–80. doi: 10.1016/j.jvs.2011.10.026